» Articles » PMID: 30513080

Cervico-vaginal Inflammatory Cytokine Alterations After Intrauterine Contraceptive Device Insertion: A Pilot Study

Overview
Journal PLoS One
Date 2018 Dec 5
PMID 30513080
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

In a prospective study of twenty sexually transmitted infection (STI)-free women, we examined the impact of an intrauterine contraceptive device (IUCD) insertion on cervico-vaginal cytokine levels. Nine women chose the levonorgestrel-containing IUCD and eight chose a copper IUCD. A cervico-vaginal swab was collected for cytokine analysis pre-insertion and four weeks post-insertion. Significant increases were noted in levels of IL-1α (median 483.4 versus 316.6 pg/mL, p = 0.046), IL-1β (median 605.7 versus 147.3 pg/mL, p = 0.018), IL-6 (median 570.1 versus 157.3 pg/mL, p = 0.046), TNFα (median 1.19 versus 0.6 pg/mL, p = 0.029) and the chemokine MCP-1 (median 340.2 versus 135.2 pg/mL, p = 0.003). No significant changes were noted in the levels of GM-CSF, IL-8, MIG, MIP-3α, RANTES, IL-10, IL-17, IP-10, MIP-1β. Whether this increase in pro-inflammatory cytokine levels decreases epithelial barrier integrity and enhances susceptibility to STIs, including HIV, merits further study.

Citing Articles

Comparative efficacy of intrauterine infusion treatments for recurrent implantation failure: a network meta-analysis of randomized controlled trials.

Jiang L, Wen L, Lv X, Tang N, Yuan Y J Assist Reprod Genet. 2025; .

PMID: 40035946 DOI: 10.1007/s10815-025-03436-2.


Neisseria gonorrhoeae induces local secretion of IL-10 at the human cervix to promote colonization.

Dai Y, Edwards V, Yu Q, Tettelin H, Stein D, Song W J Clin Invest. 2024; 135(2.

PMID: 39585777 PMC: 11735093. DOI: 10.1172/JCI183331.


Associations between common contraceptive use and circulating inflammatory biomarkers.

Mongiovi J, Babic A, Sasamoto N, Shafrir A, Huang T, Townsend M Am J Epidemiol. 2024; 194(1):85-94.

PMID: 38896053 PMC: 11735965. DOI: 10.1093/aje/kwae135.


Systems analysis reveals differential expression of endocervical genes in African women randomized to DMPA-IM, LNG implant or cu-IUD.

Gupta P, Balle C, Tharp G, Nelson S, Gasper M, Brown B Clin Immunol. 2023; 255:109750.

PMID: 37660744 PMC: 10570927. DOI: 10.1016/j.clim.2023.109750.


The Penis, the Vagina and HIV Risk: Key Differences (Aside from the Obvious).

Kaul R, Liu C, Park D, Galiwango R, Tobian A, Prodger J Viruses. 2022; 14(6).

PMID: 35746636 PMC: 9227947. DOI: 10.3390/v14061164.


References
1.
Hofmeyr G, Morrison C, Baeten J, Chipato T, Donnell D, Gichangi P . Rationale and design of a multi-center, open-label, randomised clinical trial comparing HIV incidence and contraceptive benefits in women using three commonly-used contraceptive methods (the ECHO study). Gates Open Res. 2019; 1:17. PMC: 5771152. DOI: 10.12688/gatesopenres.12775.2. View

2.
Shobokshi A, Shaarawy M . Cervical mucus granulocyte macrophage colony stimulating factor and interleukin-2 soluble receptor in women using copper intrauterine contraceptive devices. Contraception. 2002; 66(2):129-32. DOI: 10.1016/s0010-7824(02)00331-1. View

3.
Achilles S, Creinin M, Stoner K, Chen B, Meyn L, Hillier S . Changes in genital tract immune cell populations after initiation of intrauterine contraception. Am J Obstet Gynecol. 2014; 211(5):489.e1-9. PMC: 4231025. DOI: 10.1016/j.ajog.2014.05.016. View

4.
Archer D, DeSoto K, Baker J . Interleukin-6 and tumor necrosis factor-alpha concentrations in the intrauterine cavity of postmenopausal women using an intrauterine delivery system releasing progesterone. A possible mechanism of action of the intrauterine device. Contraception. 1999; 59(3):175-9. DOI: 10.1016/s0010-7824(99)00014-1. View

5.
Cortez V, Odem-Davis K, Lehman D, Mabuka J, Overbaugh J . Quotidian changes of genital tract cytokines in human immunodeficiency virus-1-infected women during the menstrual cycle. Open Forum Infect Dis. 2015; 1(1):ofu002. PMC: 4324201. DOI: 10.1093/ofid/ofu002. View